Sugi Predict

Sugi Predict / Compounds / SCHEMBL677785

SCHEMBL677785

SCHEMBL677785

Oc1ccc(C2=Cc3cc(O)c(O)cc3OC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 4/20 0.42
▸ ESR1 P03372 4/20 0.42
▸ ALOX12 P18054 2/20 0.39
▸ RARA P10276 3/20 0.38
▸ RARG P13631 3/20 0.38
▸ ALOX5 P09917 2/20 0.38
▸ RARB P10826 1/20 0.37
▸ TYR P14679 1/20 0.37
▸ APP P05067 1/20 0.37
▸ ALOX15B O15296 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ GSK3B P49841 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.34
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Idronoxil SCHEMBL149612 0.84 ESR2 (0.49) ESR2ESR1RARARARGRARB
Idronoxil SCHEMBL29353213 0.84 ESR2 (0.49) ESR2ESR1RARARARGRARB
SCHEMBL4408650 0.84 RARA (0.40) ESR2ESR1ALOX12RARARARG
SCHEMBL5962012 0.83 ALOX12 (0.45) ESR2ALOX12RARARARGALOX5
SCHEMBL2755025 0.80 KDM4E (0.42) ESR2ESR1RARARARGALOX5
SCHEMBL26549421 0.79 NISCH (0.48) ESR2ESR1RARARARGALOX5
SCHEMBL2755028 0.77 TYR (0.34) ESR2ESR1RARARARGRARB
SCHEMBL614132 0.77 ESR2 (0.50) ESR2ESR1ALOX12TYRALOX15
SCHEMBL31270617 0.77 ESR2 (0.50) ESR2ESR1ALOX12TYRALOX15
SCHEMBL615450 0.76 TYR (0.43) ESR2ESR1RARARARGRARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924713-A Diphenyl polyether modified organic silicon and preparation method and application thereof 江西三越高分子材料有限公司 2024-04-26 — — CN claimed
CN-117924713-A Diphenyl polyether modified organic silicon and preparation method and application thereof 江西三越高分子材料有限公司 2024-04-26 — — CN disclosed
US-7906554-B2 Combination chemotherapy compositions and methods NOVOGEN RESEARCH PTY LTD (AU) 2011-03-15 — — US disclosed
US-7906554-B2 Combination chemotherapy compositions and methods NOVOGEN RESEARCH PTY LTD (AU) 2011-03-15 — — US disclosed
EP-1743881-B1 Phenyl-benzyl-ketones RUANE MICHAEL (AU) 2010-12-22 — — EP disclosed
US-20100273891-A1 ISOFLAVONE METABOLITES Ruane, Michael (AU) 2010-10-28 — — US disclosed
US-20100273891-A1 ISOFLAVONE METABOLITES Ruane, Michael (AU) 2010-10-28 — — US disclosed
US-7799955-B2 Isoflavone metabolites Ruane, Michael (AU) 2010-09-21 — — US disclosed
US-7799955-B2 Isoflavone metabolites Ruane, Michael (AU) 2010-09-21 — — US disclosed
US-20100152284-A1 PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY NOVOGEN RESEARCH PTY LTD (AU) 2010-06-17 — — US disclosed
US-20090209655-A1 ISOFLAVONE METABOLITES G. J. CONSULTANTS PTY. LTD. (AU) 2009-08-20 — — US disclosed
US-20090209655-A1 ISOFLAVONE METABOLITES G. J. CONSULTANTS PTY. LTD. (AU) 2009-08-20 — — US disclosed
US-20080125481-A1 ISOFLAVONE METABOLITES JOANNOU GEORGE EUSTACE 2008-05-29 — — US disclosed
US-20080125481-A1 ISOFLAVONE METABOLITES JOANNOU GEORGE EUSTACE 2008-05-29 — — US disclosed
WO-2008052256-A1 PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY NOVOGEN RESEARCH PTY LTD (AU) 2008-05-08 — — WO disclosed
US-20080069900-A1 Combination chemotherapy compositions and methods NOVOGEN RESEARCH PTY LTD 2008-03-20 — — US disclosed
US-20080069900-A1 Combination chemotherapy compositions and methods NOVOGEN RESEARCH PTY LTD 2008-03-20 — — US disclosed
US-20070244075-A1 Isoflavonoid Prodrugs, Compositons Thereof and Therapeutic Methods Involving Same NOVOGEN RESEARCH PTY LTD 2007-10-18 — — US disclosed
US-20070244075-A1 Isoflavonoid Prodrugs, Compositons Thereof and Therapeutic Methods Involving Same NOVOGEN RESEARCH PTY LTD 2007-10-18 — — US disclosed
EP-1743881-A1 Phenyl-benzyl-ketones G.J. Consultants Pty Ltd (AU) 2007-01-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152284-A1 PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY PMP22, NGF, GAP43 ESR2 1769/4885ESR1 3617/4885ALOX12 990/4885
US-20070244075-A1 Isoflavonoid Prodrugs, Compositons Thereof and Therapeutic Methods Involving Same SI, FHIT, PYGL ESR2 544/4885ESR1 74/4885ALOX12 2275/4885
US-20100273891-A1 ISOFLAVONE METABOLITES CYP19A1, ESR1, CYP21A2 ESR2 10/4885ESR1 2/4885ALOX12 2643/4885
US-20080069900-A1 Combination chemotherapy compositions and methods TOP2A, IDH2, DHFR ESR2 631/4885ESR1 447/4885ALOX12 2670/4885
US-20090209655-A1 ISOFLAVONE METABOLITES CYP19A1, ESR1, CYP21A2 ESR2 10/4885ESR1 2/4885ALOX12 2643/4885
US-20080125481-A1 ISOFLAVONE METABOLITES CYP19A1, ESR1, CYP21A2 ESR2 10/4885ESR1 2/4885ALOX12 2643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.